1. Home
  2. OTLY vs ALT Comparison

OTLY vs ALT Comparison

Compare OTLY & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Oatly Group AB

OTLY

Oatly Group AB

HOLD

Current Price

$10.28

Market Cap

393.4M

ML Signal

HOLD

Logo Altimmune Inc.

ALT

Altimmune Inc.

HOLD

Current Price

$3.07

Market Cap

421.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OTLY
ALT
Founded
1994
1997
Country
Sweden
United States
Employees
N/A
N/A
Industry
Packaged Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
393.4M
421.5M
IPO Year
2021
2005

Fundamental Metrics

Financial Performance
Metric
OTLY
ALT
Price
$10.28
$3.07
Analyst Decision
Buy
Strong Buy
Analyst Count
5
6
Target Price
$14.50
$17.67
AVG Volume (30 Days)
59.3K
4.9M
Earning Date
04-29-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
25.37
EPS
N/A
N/A
Revenue
N/A
$41,000.00
Revenue This Year
$7.91
N/A
Revenue Next Year
$5.50
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
105.00
52 Week Low
$9.40
$2.56
52 Week High
$18.84
$7.73

Technical Indicators

Market Signals
Indicator
OTLY
ALT
Relative Strength Index (RSI) 35.32 47.28
Support Level $9.79 $2.87
Resistance Level $12.58 $4.23
Average True Range (ATR) 0.53 0.18
MACD -0.26 0.04
Stochastic Oscillator 1.35 53.68

Price Performance

Historical Comparison
OTLY
ALT

About OTLY Oatly Group AB

Oatly Group AB produces and distributes oat-based food and beverage products. Its offerings include milk, cooking creams, spreads, and yogurts. The company's products are sold through retail stores, coffee shops, and restaurants across multiple countries. It generates revenue from sales of oatmilk and other oat-based products. The company's geographical segments include Europe & International, North America and Greater China. The Europe & International segment is its maximum revenue-producing segment, followed by the North America and Greater China segments.

About ALT Altimmune Inc.

Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: